Free Trial

Trevena (TRVN) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
97,152 shs
Average Volume
159,337 shs
Market Capitalization
$7.50 million
P/E Ratio
Dividend Yield
Price Target

Trevena MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
1,150.0% Upside
$5.00 Price Target
Short Interest
0.08% of Float Sold Short
Dividend Strength
News Sentiment
0.50mentions of Trevena in the last 14 days
Based on 12 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.29) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

TRVN stock logo

About Trevena Stock (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Stock Price History

TRVN Stock News Headlines

Trevena (NASDAQ:TRVN) PT Lowered to $5.00
TRVN Stock Earnings: Trevena Beats EPS for Q1 2024
Trevena, Inc. (TRVN)
Trevena Inc TRVN
Recap: Trevena Q4 Earnings
Trevena Stock (NASDAQ:TRVN), Short Interest Report
See More Headlines
Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$3.12 million
Book Value
($0.44) per share


Free Float
Market Cap
$7.34 million
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Carrie L. BourdowMs. Carrie L. Bourdow (Age 61)
    President, CEO & Chairman
    Comp: $1M
  • Mr. Barry Shin (Age 52)
    Executive VP, COO & CFO
    Comp: $670.02k
  • Dr. Mark A. Demitrack M.D. (Age 66)
    Senior VP & Chief Medical Officer
    Comp: $690.32k
  • Dr. Howard A. Rockman M.D.
    Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon
    VP, General Counsel & Chief Compliance Officer
  • Mr. Michael Catalano
    Vice President of Marketing
  • Mr. Robert T. Yoder (Age 58)
    Senior VP, Chief Business Officer & Head of Commercial Operations
    Comp: $490.64k
  • Ms. Patricia M. Drake (Age 58)
    Senior VP & Chief Commercial Officer

TRVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevena stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings
or view top-rated stocks.

What is Trevena's stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Trevena's shares. Their TRVN share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2024?

Trevena's stock was trading at $0.7221 at the beginning of 2024. Since then, TRVN stock has decreased by 44.6% and is now trading at $0.40.
View the best growth stocks for 2024 here

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our TRVN earnings forecast

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter.

When did Trevena's stock split?

Trevena shares reverse split before market open on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?
How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVN) was last updated on 5/21/2024 by Staff

From Our Partners